Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals Inc.

Denta Water and Infra Solutions Limited ( ($IN:DENTA) ) has issued an announcement. Denta Water and Infra Solutions Limited reported audited standa...

Denta Water and Infra Solutions posts growth, renews auditors and gears up for next phase of expansion

Denta Water and Infra Solutions Limited ( ($IN:DENTA) ) just unveiled an announcement. Denta Water and Infra Solutions Limited has notified the NSE...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ENTA	$13.53	-3.01%	330.27K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ENTA	$13.53	-3.0%	330.27K
3
4
5
6

ENTA

ENTA

Dividend Overview

Get Enanta Pharmaceuticals Inc. Data in Excel

Get Enanta Pharmaceuticals Inc. Data in Excel